Yahoo
ASX - Delayed Quote AUD

Dimerix Limited (DXB.AX)

0.2100 -0.0050 (-2.33%)
At close: October 30 at 4:10:11 PM GMT+11
Chart Range Bar
Loading chart for DXB.AX
  • Previous Close 0.2150
  • Open 0.2150
  • Bid 0.2100 x --
  • Ask 0.2150 x --
  • Day's Range 0.2100 - 0.2200
  • 52 Week Range 0.1575 - 0.6650
  • Volume 333,872
  • Avg. Volume 899,495
  • Market Cap (intraday) 126.083M
  • Beta (5Y Monthly) 0.35
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0500
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date Sep 24, 1999
  • 1y Target Est 1.89

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury. The company is headquartered in Fitzroy, Australia.

dimerix.com

15

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

DXB.AX
61.82%
S&P/ASX 200 [XJO] (^AXJO)
2.22%

1-Year Return

DXB.AX
57.14%
S&P/ASX 200 [XJO] (^AXJO)
0.25%

3-Year Return

DXB.AX
23.53%
S&P/ASX 200 [XJO] (^AXJO)
31.53%

5-Year Return

DXB.AX
16.19%
S&P/ASX 200 [XJO] (^AXJO)
21.63%

Analyst Insights

View More

Analyst Price Targets

1.89
1.89 Average
0.2100 Current
1.89 High

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -29.36%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    6.35M

  • Net Income Avi to Common (ttm)

    -29.81M

  • Diluted EPS (ttm)

    -0.0500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    16.15M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -48.46M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: